UPDATE: Piper Jaffray Upgrades Arena Pharma to Overweight and Raises PT to $3 - Charles River (NYSE:CRL)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

A report from Piper Jaffray upgrades its rating from Neutral to Overweight and raises its price target from $1.50 to $3 on Arena Pharmaceuticals (NASDAQ: ARNA).The report states, “We are upgrading Arena to Overweight from Neutral ahead of the lorcaserin New Drug Application (NDA) re-submission around year-end. While regulatory risk remains, Arena has made substantial progress addressing the FDA's requests in the Complete Response Letter (CRL). We believe the final requirements necessary for re-filing are female rat mammary tumor data and in vitro receptor activity work.”ARNA closed Friday at $1.27.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!